Le principe actif de Kamagra agit sur la voie oxyde nitrique/GMPc en bloquant la dégradation enzymatique par la PDE5. Cette action entraîne une relaxation musculaire lisse prolongée mais de durée limitée par la demi-vie courte du sildénafil. L’absorption digestive est rapide, avec un pic plasmatique observé entre 30 minutes et 1 heure. Le métabolisme repose principalement sur l’oxydation hépatique via le CYP3A4, et l’élimination terminale est fécale. Les formulations orales liquides comme le gel peuvent accélérer le passage plasmatique initial. Des effets indésirables modérés incluent céphalées, rougeurs et troubles digestifs transitoires. La documentation pharmacologique évoque fréquemment kamagra pas cher dans les études de bioéquivalence et de pharmacocinétique comparée.

Shergillurology.com

Global Speaker Development Meeting
Barcelona, Spain
26 – 27 January 2008
DRAFT Agenda
Saturday, 26 January

7.00 – 8.00
Breakfast

8.00 – 8.15
Welcome and Introduction
8.15 – 8.30
Discussion of Fesoterodine and Tolterodine in the Marketplace
Jorg Bruggemann
Pfizer Inc

8.30 – 9.15
Improving upon the OAB Gold Standard: Opportunity for Dose
Individualisation
Christopher Chapple, MD, BSc, FRCS, FEBU  Question & Answer Session
9.15 – 10.00
The Link between Fesoterodine and Tolterodine: Pre-clinical and
Early Clinical Data
Martin Michel, MD
 Question & Answer Session
10.00 – 10.15
9.45 – 12.00
Fesoterodine Efficacy, Safety and Tolerability, Demonstrated in
Phase 3 Studies

 Phase 3 Study Design and Efficacy Results from the US
Study (SP584)
Eric Rovner, MD

 Efficacy Results from the International Study (SP583) and
Combined Phase 3 Safety and Tolerability Results
Andrea Tubaro, MD, PhD

 Question & Answer Session
12.00 – 13.00
Saturday, 26 January (cont’d)

13.00 – 14.00
Fesoterodine Promotional Slide Kit

 Fesoterodine Profile Established in Pre-clinical and Phase
1 and 2 Clinical Trials
Klaus-Peter Jünemann, MD, PhD

 Fesoterodine Efficacy, Safety and Tolerability as
demonstrated in Phase 3 Trials
Paul Abrams, MD, FRCS

14.00 – 14.30
Question & Answer Session

14.30 – 14.45
Overview of Case Studies
Sender Herschorn, MD, FRCSC
14.45 – 15.15
Case Study 1
56 Year Old Female – Treatment Naive
Question & Answer Session
Sender Herschorn, MD, FRCSC

15.15 – 15.45
Case Study 2
72 Year Old Male – Treatment Naive
Question & Answer Session
Klaus-Peter Jünemann, MD, PhD

15.45 – 16.15
Case Study 3
63 Year Old Male - Previously Treated
Question & Answer Session
Klaus-Peter Jünemann, MD, PhD

16.15 – 16.30
Overview of Sunday’s Workshops and Closing Remarks
Marina Brodsky, PhD
Pfizer Inc

Dinner (offsite)
Sunday, 27 January

7.30 – 8.15
Breakfast

8.15 – 8.30
Introduction to Day 2
Marina Brodsky, PhD
Pfizer Inc

8.30 – 9.00
Potential Applications of Nanotechnology in Urology
Iqbal S. Shergill, BSc, MB,BS, MRCS
Guest Speaker

9.15 – 12.00
Workshop Overview and Assignments

Workshop Sessions
Faculty Members:
Paul Abrams, MD, FRCS
Linda Cardozo, MD
Christopher Chapple, MD, BSc, FRCS, FEBU
Roger Dmochowski, MD
Sender Herschorn, MD, FRCSC
Klaus-Peter Jünemann, MD, PhD
Steven Kaplan, MD, FACS
David Sussman, DO, FACOS
Andrea Tubaro, MD, PhD

12.00 – 13.00
Lunch (Optional)
Departures

Source: http://www.shergillurology.com/Pfizer-Global-Development-Meeting-Barcelona-2008.pdf